<DOC>
	<DOCNO>NCT00791856</DOCNO>
	<brief_summary>This open-label , multiple-dose , randomize , two-period crossover bioequivalence study approximately 110 surgically naturally postmenopausal woman stable hormone therapy ( i.e. , estrogen surgically postmenopausal woman continuous regimen estrogen plus progestin naturally postmenopausal woman ) restrict approved oral transdermal regimen , concomitant hormone therapy .</brief_summary>
	<brief_title>Bioequivalence Testosterone Reduced-size Patch Relative Testosterone Reference Patch</brief_title>
	<detailed_description />
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>surgically postmenopausal female 20 70 year age hysterectomy bilateral oophorectomy least 6 month prior screen , healthy naturally postmenopausal female 50 70 year age experience amenorrhea least 12 month prior screen ; good general health base medical history , physical examination , laboratory evaluation ; mammogram , clinically significant abnormality , within precede 12 month subject &gt; 40 year age ; stable dose approve hormone therapy restrict oral transdermal regimen ( vaginal product acceptable ) period least 12 week prior screen : estrogen surgically postmenopausal woman , estrogen naturally postmenopausal woman hysterectomized , continuous regimen estrogen plus progestin naturally postmenopausal woman hysterectomized hormone therapy ( stop hormone therapy least 12 week prior screen ; uncontrolled acute disease major surgical operation require hospitalization within 1 month screening ; uncontrolled chronic disease , hypertension ( diastolic blood pressure &gt; 95 mm Hg medication ) , systemic lupus erythematosus , rheumatoid arthritis ; history myocardial infarction , bypass surgery , stroke , pulmonary embolism , deep vein thrombosis ; history cancer within last 5 year ( except basal cell carcinoma document 6 month remission ) , abnormal vaginal bleeding , tuberculosis ; uncontrolled diabetes mellitus HbA1C &gt; 7.5 % ( Note : subject diabetes mellitus fast serum glucose level screen visit laboratory 's upper limit normal reference range HbA1C test prior randomization . ) ; abnormal clinical laboratory value screen assess clinically significant Investigator ; serum thyroid stimulate hormone ( TSH ) value outside normal laboratory range , confirm free T4 level outside normal laboratory range ; current severe dermatological problem ( e.g. , severe cystic acne ) , include concomitant skin disease history druginduced contact dermatitis ; participate cumulative irritation test within past 12 week , know suspected hypersensitivity allergy transdermal system include component patch use study ; currently use history androgen treatment within 6 month prior screen , use dehydroepiandrosterone 25 mg per day , St. John 's Wort within 4 week prior baseline . Due large number herbal remedy available , herbal supplement review Sponsor screening ;</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>